OIS@AAO

The principals of LacriScience – Paul T. Gavaris, MD, managing member and CEO, LacriScience, Chris D. Geddes, PhD, chief biomedical and Ali Ghovanlou,plasmonics consultant– deliver…

David Pyott, former CEO, Allergan, doesn’t mince words. He explains why he took such an aggressive stance against Valeant’s bid to buy his former company.…

Newly appointed CEO Reza Zadno, PhD, explains why he found Avedro to be such a promising opportunity. Rajesh Rajpal, MD, Chief Medical Officer, discusses two…

Nancy Lurker explains why she took over as CEO and president at pSivida and gives details on the company’s “outstanding” results of early clinical testing…

Sensimed CEO David Bailey recounts his maiden presentation to OIS and shares information on the company’s recent financing, including a commitment from a new strategic…

Robert Dempsey, head of the ophthalmics franchise for Shire, lays out how Shire rolled out the commercial launch of Xiidra, the company’s new potential blockbuster…

Monty Montoya, CEO, introduces SightLife Surgical, the for-profit subsidiary of SightLife that he says will enable the group to complete its mission of eliminating treatable…

OIS Co-Chair Emmett T. Cunningham Jr., MD, PhD, MPH laid out hopeful – and cautionary – signs facing the ophthalmology industry as he kicked off…